RhumbLine Advisers’s XBiotech XBIT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.18K | Hold |
928
| – | – | ﹤0.01% | 3932 |
|
|
2025
Q4 | $2.22K | Hold |
928
| – | – | ﹤0.01% | 3985 |
|
|
2025
Q3 | $2.47K | Hold |
928
| – | – | ﹤0.01% | 3971 |
|
|
2025
Q2 | $2.76K | Sell |
928
-18,539
| -95% | -$53.9K | ﹤0.01% | 3968 |
|
|
2025
Q1 | $63.1K | Sell |
19,467
-277
| -1% | -$955 | ﹤0.01% | 3523 |
|
|
2024
Q4 | $78K | Sell |
19,744
-1,506
| -7% | -$10.3K | ﹤0.01% | 3546 |
|
|
2024
Q3 | $164K | Buy |
21,250
+1,156
| +6% | +$7.59K | ﹤0.01% | 3330 |
|
|
2024
Q2 | $103K | Buy |
20,094
+19,341
| +2,569% | +$149K | ﹤0.01% | 3510 |
|
|
2024
Q1 | $6.12K | Hold |
753
| – | – | ﹤0.01% | 3951 |
|
|
2023
Q4 | $3.01K | Hold |
753
| – | – | ﹤0.01% | 4054 |
|
|
2023
Q3 | $3.1K | Hold |
753
| – | – | ﹤0.01% | 4056 |
|
|
2023
Q2 | $4.47K | Buy |
+753
| New | +$3.4K | ﹤0.01% | 4113 |
|
|
2022
Q2 | – | Sell |
-18,748
| Closed | -$162K | – | 3251 |
|
|
2022
Q1 | $162K | Sell |
18,748
-1,962
| -9% | -$19.7K | ﹤0.01% | 2801 |
|
|
2021
Q4 | $231K | Sell |
20,710
-535
| -3% | -$6.96K | ﹤0.01% | 2794 |
|
|
2021
Q3 | $275K | Buy |
21,245
+860
| +4% | +$13.7K | ﹤0.01% | 2801 |
|
|
2021
Q2 | $338K | Sell |
20,385
-1,844
| -8% | -$31.3K | ﹤0.01% | 2739 |
|
|
2021
Q1 | $382K | Sell |
22,229
-680
| -3% | -$12.7K | ﹤0.01% | 2611 |
|
|
2020
Q4 | $359K | Buy |
22,909
+3,131
| +16% | +$57.7K | ﹤0.01% | 2589 |
|
|
2020
Q3 | $378K | Sell |
19,778
-3,320
| -14% | -$57.3K | ﹤0.01% | 2416 |
|
|
2020
Q2 | $317K | Buy |
23,098
+6,663
| +41% | +$93.6K | ﹤0.01% | 2553 |
|
|
2020
Q1 | $175K | Sell |
16,435
-2,505
| -13% | -$40.8K | ﹤0.01% | 2635 |
|
|
2019
Q4 | $354K | Buy |
18,940
+5,269
| +39% | +$67.8K | ﹤0.01% | 2516 |
|
|
2019
Q3 | $143K | Buy |
13,671
+450
| +3% | +$3.67K | ﹤0.01% | 2823 |
|
|
2019
Q2 | $100K | Buy |
+13,221
| New | +$115K | ﹤0.01% | 2932 |
|
|
2018
Q2 | – | Sell |
-17,371
| Closed | -$93K | – | 2931 |
|
|
2018
Q1 | $93K | Sell |
17,371
-300
| -2% | -$1.38K | ﹤0.01% | 2748 |
|
|
2017
Q4 | $70K | Hold |
17,671
| – | – | ﹤0.01% | 2801 |
|
|
2017
Q3 | $77K | Buy |
17,671
+520
| +3% | +$2.46K | ﹤0.01% | 2876 |
|
|
2017
Q2 | $81K | Sell |
17,151
-1,706
| -9% | -$16.3K | ﹤0.01% | 2904 |
|
|
2017
Q1 | $311K | Buy |
18,857
+550
| +3% | +$7.2K | ﹤0.01% | 2487 |
|
|
2016
Q4 | $185K | Buy |
18,307
+3,563
| +24% | +$47.4K | ﹤0.01% | 2694 |
|
|
2016
Q3 | $198K | Buy |
14,744
+1,400
| +10% | +$20.5K | ﹤0.01% | 2683 |
|
|
2016
Q2 | $279K | Buy |
+13,344
| New | +$193K | ﹤0.01% | 2574 |
|
Other funds holding XBIT
VCM
RC
BCM
VFT
RhumbLine Advisers's XBIT Position: Q1 2026 in Review
RhumbLine Advisers held its XBiotech (XBIT) position steady in Q1 2026 at 928 shares worth $2.18K. The position accounts for ﹤0.01% of the portfolio, ranked #3932.
RhumbLine Advisers first reported a position in XBIT in Q2 2016 and has held it in 32 quarters since. The position peaked at $382K in Q1 2021. 37 funds tracked by Wall St. Rank hold XBIT as of Q1 2026.
- RhumbLine Advisers held 928 shares of XBiotech worth $2.18K as of Q1 2026.
- RhumbLine Advisers left its XBiotech share count unchanged in Q1 2026.
- XBiotech made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3932 holding.
- RhumbLine Advisers first reported a position in XBiotech in Q2 2016 and has held it in 32 quarters since.
- RhumbLine Advisers's XBiotech position peaked at $382K in Q1 2021.
- 37 funds tracked by Wall St. Rank held XBiotech as of Q1 2026.
Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.